[7] In other tumor types such as BRAF-aberrant melanoma, or EGFR- or ALK-aberrant NSCLC, significant improvements have been achieved by matching targeted agents with patients harboring the cognate molecular abnormality. This evidence concerns the gene ALK and non-small cell lung carcinoma.